Patents by Inventor Loretta L. Delehanty

Loretta L. Delehanty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8952061
    Abstract: The present invention discloses the signaling pathway involved erythroid repression by iron deficiency. Further disclosed is anon-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: February 10, 2015
    Assignee: University of Virginia Patent Foundation
    Inventors: Adam N. Goldfarb, Loretta L. Delehanty
  • Publication number: 20130072428
    Abstract: The present invention discloses the signaling pathway involved erythroid repression by iron deficiency. Further disclosed is anon-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.
    Type: Application
    Filed: November 19, 2012
    Publication date: March 21, 2013
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Adam N. Goldfarb, Loretta L. Delehanty
  • Publication number: 20120142590
    Abstract: The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.
    Type: Application
    Filed: October 14, 2011
    Publication date: June 7, 2012
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Adam N. Goldfarb, Loretta L. Delehanty
  • Publication number: 20100184643
    Abstract: The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakary-ocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.
    Type: Application
    Filed: August 22, 2007
    Publication date: July 22, 2010
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Adam N. Goldfarb, Loretta L. Delehanty